# OnCo record bl-b01d1-307 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/bl-b01d1-307/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "bl-b01d1-307", "NCT06382142" ;
  schema:name "BL-B01D1-307"@en ;
  schema:description "The first phase 3 win for a bispecific ADC, in triple-negative breast cancer, announced February 2026."@en ;
  schema:url <https://onco.cc/trials/bl-b01d1-307/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06382142>, <https://www.targetedonc.com/view/iza-bren-meets-pfs-and-os-end-points-in-phase-3-tnbc-trial> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2024-06-21" ;
  onco:related <https://onco.cc/collections/src-targeted-oncology/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-adc/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/> .